CAJ | 학술논문

目的探讨原发性腮腺恶性淋巴瘤的临床、病理特点及治疗、预后.方法回顾性分析24例原发性腮腺淋巴瘤患者的病理类型、分期、治疗,应用Kaplan-Meier法行生存分析和Log-Rank检验法行差异显著性检验.结果全组5年无进展生存率为79.2%、总生存率为83.3%;19例黏膜相关淋巴组织淋巴瘤(MALTL)和Ⅰ、Ⅱ级滤泡型淋巴瘤(FL)的5年无进展生存率为89.5%、总生存率为94.7%,其中接受化疗(9例)与未接受化疗(10例)的两组患者的5年无进展生存率(88.9%与90.0%)和总生存率(100%与90.0%)比较差异均无统计学意义.结论腮腺淋巴瘤发病率低,分期一般为早期,病理类型多为低度恶性B细胞型非霍奇金淋巴瘤,总体预后较好.早期低度恶性患者可单纯行手术和(或)放疗的局部治疗,而对于侵袭性弥漫性大B细胞淋巴瘤(DLBCL),化放疗联合的综合治疗可能是最佳选择.
목적 탐토원발성시선악성림파류적림상、병리특점급치료、예후.방법 회고성분석24례원발성시선림파류환자적병리류형、분기、치료,응용Kaplan-Meier법행생존분석화Log-Rank검험법행차이현저성검험.결과 전조5년무진전생존솔위79.2%、총생존솔위83.3%;19례점막상관림파조직림파류(MALTL)화Ⅰ、Ⅱ급려포형림파류(FL)적5년무진전생존솔위89.5%、총생존솔위94.7%,기중접수화료(9례)여미접수화료(10례)적량조환자적5년무진전생존솔(88.9%여90.0%)화총생존솔(100%여90.0%)비교차이균무통계학의의.결론 시선림파류발병솔저,분기일반위조기,병리류형다위저도악성B세포형비곽기금림파류,총체예후교호.조기저도악성환자가단순행수술화(혹)방료적국부치료,이대우침습성미만성대B세포림파류(DLBCL),화방료연합적종합치료가능시최가선택.
Objective To discuss the clinical and pathological characteristics, treatment results and prognosis of primary parotid malignant lymphoma. Methods Pathological subtypes, clinical stages and treatment of the 24 patients with primary parotid malignant lymphoma were retrospectively analysed. Kaplan-Meier method was used in the survival analysis and Log-Rank method was used in the statistic study. Results The 5-year progression free survival (PFS) and overall survival (OS) were 79.2 % and 83.3 %, respectively. The 5-year PFS and OS were 89.5 % and 94.7 % for 19 patients with low-grade malignant lymphoma (including MALTL and Ⅰ/Ⅱ grade FL). The differences of the 5-year PFS and OS of 9 patients received chemotherapy and of 10 patients with on chemotherapy had no statistical significance. Conclusion The incidence of primary parotid malignant lymphoma is low, at earlier clinical stage, and most of its pathological subtype were B-cell low-grade malignant non-Hodgkin lymphoma. Surgery and/or radiotherapy should be the first choice for patients with early stage low-grade malignant lymphoma, whereas combined modality therapy was probably the best choice for patients with DLBCL.